AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer

AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer

Shots:

  • The P-III CASPIAN study involves assessing of Imfinzi + etoposide + cisplatin/carboplatin or Imfinzi + tremelimumab + CT vs CT as monothx. as a 1L treatment for patients with extensive-stage SCLC across 22 countries including the US & EU
  • The P-III CASPIAN study resulted in meeting its 1EPs i.e, improvement in overall survival in SCLC patients. The safety & tolerability of combination therapy is consistent with the known safety profile
  • Imfinzi is a mAb targeting PD-L1, act by blocking the interaction of PD-L1 with PD-1 and CD80 and is an approved therapy in 45+ countries including the US, EU & Japan based on P-III PACIFIC study for unresectable, Stage III NSCLC

Click here to read full press release/ article | Ref: AstraZeneca | Image: The Guardian